BTA is cheap as chips... I'm in and won't be selling any time soon. LANI and HRV trial results + possible Relenza stockpiling is a pretty good bet I say. There are not many companies that have 50% access to a fully funded phase III drug that could be a "blockbuster".... well not at these market caps anyway.
Only trouble with Biota is that there are alot of other "punt" stocks taking the speculative dollars. At these prices I wouldn't be surprised if the board decided to buy back another load of stock.
Add to My Watchlist
What is My Watchlist?